Literature DB >> 7679376

Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.

D E Schiff1, C A Wass, S J Cryz, A S Cross, K S Kim.   

Abstract

Serum obtained after immunization with an O18 polysaccharide-toxin A conjugate vaccine was evaluated for the estimation of protective levels of anti-O-specific lipopolysaccharide (LPS) immunoglobulin G (IgG) antibody against bacteremia and death caused by a homologous serotype of Escherichia coli K1 strains. Passive transfer of rabbit serum conferred significant protection from a lethal E. coli infection in a neonatal rat model. The overall incidence of bacteremia and mortality was 4% in rat pups receiving undiluted postvaccination serum, while that in control animals was 100% (P < 0.001). The overall incidences of bacteremia were 5 and 72% for animals with serum anti-O18 LPS IgG concentrations of > 1.0 and < 1.0 microgram/ml, respectively, while the overall incidences of mortality for animals with serum anti-O18 LPS IgG levels of > 1.0 and < 1.0 microgram/ml were 0 and 72%, respectively (P < 0.001). Protection against E. coli infection was also demonstrated with human anti-O18 polysaccharide IgG. None of the animals with human anti-O18 LPS IgG levels of > 1 microgram/ml had bacteremia after bacterial challenge, whereas all animals with bacteremia at 18 h had levels of < 1 microgram/ml. These findings suggest that serum anti-O18 LPS IgG concentrations of > 1.0 microgram/ml may provide protection against bacteremia and death caused by a homologous E. coli K1 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679376      PMCID: PMC302828          DOI: 10.1128/iai.61.3.975-980.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

Review 1.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

2.  Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.

Authors:  K S Kim; J H Kang; A S Cross; B Kaufman; W Zollinger; J Sadoff
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

3.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

4.  High-dose intravenous immune globulin impairs antibacterial activity of antibiotics.

Authors:  K S Kim
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793

5.  Bacteremia in a long-term care facility. Spectrum and mortality.

Authors:  U Setia; I Serventi; P Lorenz
Journal:  Arch Intern Med       Date:  1984-08

6.  Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1.

Authors:  G Pluschke; M Achtman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Relative functional activity of purified human immunoglobulin G against a type III group B streptococcal strain.

Authors:  K S Kim; J H Kang; N F Concepcion; B F Anthony
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

8.  Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.

Authors:  S J Cryz; E Fürer; J C Sadoff; T Fredeking; J U Que; A S Cross
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.

Authors:  S J Cryz; A S Cross; J C Sadoff; A Wegmann; J U Que; E Fürer
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 7.759

10.  Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.

Authors:  S J Cryz; A S Cross; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.609

View more
  4 in total

1.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

2.  Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers.

Authors:  Vladimir Petrušić; Irena Zivković; Marijana Stojanović; Ivana Stojićević; Emilija Marinković; Aleksandra Inić-Kanada; Ljiljana Dimitijević
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

3.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

4.  Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.

Authors:  So-Yon Lim; Adam Bauermeister; Richard A Kjonaas; Swapan K Ghosh
Journal:  J Immune Based Ther Vaccines       Date:  2006-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.